News

Filter

Current filters:

Ambien

1 to 9 of 164 results

Product sales in 2010: hits and misses, assessed by EvaluatePharma

14-06-2011

In contrast to huge volatility in 2009 when the swine flu pandemic caused global stockpiling of potential…

AmbienFinancialMarkets & MarketingNovo NordiskPfizerPharmaceuticalProtonixSanofiVictoza

US FTC warns Sanofi, Watson and Synthon over Ambien patent deal, but won’t take action

11-05-2011

The Federal Trade Commission’s Bureau of Competition has notified Sanofi-Aventis US, a subsidiary…

AmbienGenericsLegalNorth AmericaPatentsPharmaceuticalSanofi-AventisSynthonWatson Pharmaceuticals

Lunesta misses Ph II efficacy endpoints

16-03-2009

US drugmaker Sepracor's Lunesta (eszopiclone) failed to demonstrate efficacy in a mid-stage trial, assessing…

AmbienAventis PharmaEszopicloneHamiltonLunestaSanofi-AventisZolpidem Tartrate

Survey finds US mail order patients switch to generics

29-09-2008

Two surveys by US pharmacy benefit manager Express Scripts has found that patients who use a home delivery…

AmbienAventis PharmaSanofi-AventisZolpidem Tartrate

1 to 9 of 164 results

Back to top